Study of Belantamab mafodotin treatment for patients with relapsed/refractory myeloma via gsk expanded access program: real-world data
Latest Information Update: 16 Jan 2023
At a glance
- Drugs Belantamab mafodotin (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- 01 Jan 2023 Results published in the British Journal of Haematology
- 04 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association